Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
what a down day wow ..have not had one of these in awhile
yep and issued huge offering today 30m
VRML the one bright spot
Vermillion Receives Category 1 CPT Code Approval for OVA1
logo unavailable
AUSTIN, Texas, March 6, 2012 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Panel has voted to approve an application for a Category 1 CPT code for its OVA1® test, which is designed to help differentiate benign versus malignant ovarian masses.
The AMA recently disclosed the new code on its website, which will become effective January 1, 2013.
"This is a major achievement for OVA1 and an endorsement for the unmet clinical need addressed by this important triage test," said Gail S. Page, Vermillion's president and chief executive officer. "This approval was supported by several peer-reviewed publications and positive coverage decisions, including Medicare. The new CPT code is a critical step in advancing the commercialization of OVA1, as we believe it will help streamline claims processing and accelerate further coverage and adoption by private payers."
About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at www.vermillion.com.
Forward-Looking Statement
Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives,
gm..yah and PROT..both sick moves..not much premarket today
yah saw it ..mean to keep track but oh well
AEZS closed highs 2.20
SLMU unreal hit .14 from .02
Whole family killed by the tornado..so heartbreaking Miracle story of baby dropped in field ends sadly
Loading... Share No Thanks Must Read?Thank YouYes 298
Email Story Print
By TOM LoBIANCO and BRUCE SCHREINER, AP
2 hours ago
news-general-20120303-US.Severe.Weather
Snow covers a demolished house in Marysville, Ind., Monday, March 5, 2012 af...
LOUISVILLE, Ky. — Fifteen-month-old Angel Babcock seemed to be the miracle survivor of a deadly tornado that killed her parents and two siblings when she arrived Friday night at Kosair Children's Hospital in Louisville, Ky. Though critically injured when the twister scooped her up and deposited her in a field, Angel was opening her eyes. Hospital workers said that was a hopeful sign.
But the New Pekin, Ind., girl's condition deteriorated Saturday as her brain swelled, chief nursing officer Cis Gruebbel said. As the day went on, Angel's eyes stopped moving, and there was no sign of brain activity. She was removed from life support Sunday afternoon.
"I had my arm around her when she took her last breath," her grandmother, Kathy Babcock, told ABC News. "I sang to her `Itsy-bitsy spider.'"
Angel's death ended a hopeful tale for survivors in the Midwest and South and brought to 39 the number of people killed by the storms that devastated five states.
As residents picked through the rubble and made plans to bury their dead, they also began trying to find a semblance of normalcy as officials continued to assess the damage.
The National Weather Service in Louisville, Ky., said the tornado that struck New Pekin measured an EF-3 on the enhanced Fujita scale, while another tornado that struck nearby Henryville, Ind., was stronger yet, measuring an EF-4 and packing winds of 175 mph.
Early Monday, a blanket of wet snow covered Henryville and other parts of tornado-stricken Clark County. State homeland security spokeswoman Emily Norcross said the 2 to 4 inches of snow could slow cleanup efforts because it concealed potential hazards.
"It's slippery and it's hampering visibility on roads, so it's more difficult to see small debris like nails," Norcross said. "It's complicating things."
Theresa McCarty, owner of Pop Top Bar in New Pekin, said her husband was with emergency workers Friday when they found the Babcock family. Their bodies had been scattered, she said.
McCarty, her friends and co-workers talked about establishing the bar as a central refuge for tornado victims from the immediate region, including making roughly 1,000 meals Sunday for victims and volunteers.
But when she talked about the Babcock family, she got quiet: "It was the whole family."
Speaking from his bed at the University of Louisville Hospital, Jason Miller told NBC's "Today" show Monday that he invited the Babcock family into his home as the storm was bearing down. As it hit, they took shelter in the hallway, grabbed hands and began to pray.
Miller said he remembers being sucked up into the air but blacked out soon after. His arm, back and five ribs were broken.
"It's very saddening to hear that the whole family passed away, and I was sitting right there holding their hands two seconds before they died," Miller said.
A memorial service for the Babcock family was scheduled for Monday afternoon at a church in Salem, Ind.
Indiana Gov. Mitch Daniels told CBS' "Face the Nation" that the twister "moved like a lawnmower though some of the most beautiful countryside, and some of the most beautiful towns that we have."
A story of hope emerged from North Carolina, where three children survived after being torn from their beds by a tornado early Saturday. The twister sucked Jamal Stevens, 7, from his room and threw him about 100 feet from his Charlotte area home to land alongside an interstate. His 3- and 4-year old sisters were found in nearby yards. All three were released from a hospital Sunday.
In Henryville, about 20 miles north of Louisville, school was canceled for the week because of heavy damage to the education complex housing elementary through high school students.
Even so, small signs of normalcy emerged. Utility crews replaced downed poles and restrung electrical lines. Portable cell towers went up, and a truck equipped with batteries, cellphone charging stations, computers and satellite television was headed to Henryville on Monday.
"We're going to keep living," said the Rev. Steve Schaftlein during a Sunday service at St. Francis Xavier Catholic Church, where about 100 people gathered under a patched-up 6-foot hole in the roof to worship and catch up on news of the tornado.
Even with life upended in so many ways, one family got a reminder that the deadly tornado hadn't changed everything.
The home that Shalonda Kerr shares with her husband and Jack Russell terrier outside of Chelsea, Ind., was obliterated: The front wall was ripped clean, leaving the home looking eerily like a shaken dollhouse. An upended couch and a tipped-over fish tank lay in the rubble.
The mailbox was untouched. Its front hatch was tipped open, revealing a white piece of paper.
"Inside was a $300 IRS bill," Kerr said, laughing amid the ruins.
___
Schreiner reported from West Liberty, Ky. Jason Keyser in Marysville, Ind., and Rick Callahan in Indianapolis contributed to this report.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Loading... Share No Thanks Must Read?Thank YouYes 298
Email Story Print
View Next Article: Limbaugh says his apology to student was
ALIM same to u..lol
Bork back to .56 go down to .43 pleeze
me too weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
he is so fresh lol
Like that little piggy on tv? rofffffffffffff
PRKR could be nice (COMTEX) B: ParkerVision Announces Markman Hearing in Patent Infringement
B: ParkerVision Announces Markman Hearing in Patent Infringement Lawsuit Against
JACKSONVILLE, Fla., Feb. 15, 2012 /PRNewswire via COMTEX/ --
ParkerVision, Inc. (NASDAQ: PRKR), a developer and marketer of semiconductor
technology solutions for wireless applications, announced today that U.S.
District Judge Roy B. Dalton Jr. has established a schedule for upcoming
hearings and other case deadlines in ParkerVision Inc. v. Qualcomm Inc., No.
3-2011-cv-00719, a patent infringement lawsuit filed by ParkerVision against
San-Diego based Qualcomm, Inc. (NASDAQ: QCOM).
The patent claim construction hearing, also called a Markman hearing, is set
for August 10, 2012, at which time the judge will be asked to issue rulings
regarding the language and interpretation of the ParkerVision patents at
issue in the case. Markman hearings are considered a critical event in a
patent lawsuit. The upcoming Markman ruling will define the property rights
for the technologies that ParkerVision has invented and has the right to
exclusively practice. The court's Markman hearing decisions will drive and
inform many aspects of the litigation. The jury trial in this case is
scheduled to begin on August 5, 2013.
"We are passionate about the technology that ParkerVision has developed, and
we are committed to protecting our patented innovations from unauthorized
use," stated Jeffrey L. Parker, Chairman and Chief Executive Officer of
ParkerVision. "We look forward to showing the court and jury how Qualcomm is
using ParkerVision's technology despite the legal patent protections that we
have expended a great deal of time and capital to secure. This firm timeline
means that we will soon get our day in court."
In other key developments, the court denied as moot Qualcomm's motion for
preliminary injunction against ParkerVision's patent prosecution counsel.
Instead, the Court approved a protective order, which all parties negotiated
and agreed to, that enables ParkerVision's patent prosecution counsel to
continue delivering legal advice and services to ParkerVision provided that
they do not represent ParkerVision in the lawsuit or advise the company
regarding Qualcomm's alleged infringement.
Both of these developments stem from a lawsuit that ParkerVision filed
against Qualcomm on July 20, 2011, in the U.S. District Court for the Middle
District of Florida. ParkerVision brought this action because Qualcomm's
past and current chipset products infringe several ParkerVision patents
related to radio-frequency receivers and the down-conversion of
electromagnetic signals, which represent a body of intellectual property that
ParkerVision pioneered for creating direct conversion receivers.
ParkerVision's lawsuit seeks monetary damages from Qualcomm as well as a
oops
yah not suggesting buying here..still not great chart
LJPCD has recent 8k and something about a patent being issed this week already did r/s so small float..could be one to watch real close.. On February 23, 2012, La Jolla Pharmaceutical Company (the “Company”) received from the U.S. Patent and Trademark Office a notification of issuance for the Company’s patent application covering certain claims relating to GCS-100, a galectin-3 inhibitor that is being studied for the treatment of cancer and chronic organ failure. The patent is expected to issue on or about March 6, 2012 and will expire on March 13, 2028, without giving effect to any potential patent term extensions that may be available in the future under the Hatch-Waxman Amendments to the Drug Price Competition and Patent Term Restoration Act of 1984.
* * *
JOEZ nice flips still..
KUTV 2.51 now
BORK .61x.63 now..still at support
CBLI3.30 at support again
CBK bottom watch again
GALE hits 1.64 been posting on it from .60's lol
LJPCD .06 now
SCEI sick still
ROYL WEEEE
wavx bounce
GALE 1.52 pre now
BPAX wonder if this can break .85 today
TSON gapped on news
AEZS bio looks like AFFY at bottom before it went to 10 bucks
GM..sounds like sage advice..thanks for sharing
BPAX gapped on news (COMTEX) B: BioSante's Prostate Cancer Vaccine Resulted in Stable Disease
in Over 50% of Patients in Newly Published Study ( Bus
B: BioSante's Prostate Cancer Vaccine Resulted in Stable Disease in Over 50% of
Patients in Newly Published Study ( BusinessWire )
LINCOLNSHIRE, Ill., Mar 05, 2012 (BUSINESS WIRE) --
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced
publication of results from a Phase I dose escalation clinical study
that show its GVAX Prostate cancer vaccine in treating metastatic
castration-resistant prostate cancer patients (mCRPC) in combination
with ipilimumab (Ipi; Yervoy; BMS), resulted in 53 percent of patients
achieving at least stable disease, with two patients showing clear
regression of metastases. In addition, 23 percent of patients in the
higher dose cohorts had confirmed partial PSA (prostate specific
antigen) responses of greater than 50 percent from baseline.
The study, titled, "Combined Immunotherapy with Granulocyte-Macrophage
Colony-Stimulating Factor-Transduced Allogeneic Prostate Cancer Cells
and Ipilimumab in Patients with Metastatic Castration-Resistant
Prostate
Cancer: a Phase 1 Dose Escalation Trial" was published in current issue
of The Lancet Oncology (February 2012). The study combined fixed doses
of GVAX Prostate in combination with escalating 0.1, 0.3, 1.0, 3.0 and
5.0 mg/kg doses of Ipi. The study enrolled 12 patients in three dose
escalation cohorts and 16 patients in an expansion Ipi 3.0 mg/kg
cohort.
The reported duration of disease stabilization ranged from 3-27 months,
and the median duration of PSA response was 12 months, (range 2-21
months). There were no serious adverse events in the lower dose Ipi
cohorts and administration of immunotherapy was well tolerated and
safe.
The investigators concluded that, "Further research on the combined
treatment of patients with mCRPC with vaccination and Ipilimumab is
warranted."
The 28 patient Phase I study was conducted by researchers at the VU
University Medical Centre in Amsterdam, Netherlands. BioSante's
Prostate
cancer vaccine is made from allogeneic prostate cancer cells
genetically
altered to produce an immune system stimulator called GM-CSF, and
irradiated to prevent cell growth. A Phase II GVAX Prostate clinical
trial is anticipated to begin in 2012 at the Johns Hopkins Sidney
Kimmel
Comprehensive Cancer Center.
"We are very excited by the positive results of this prostate cancer
study notably combined with recently reported excellent results in
pancreatic cancer. This is encouraging news concerning the potential
for
GVAX cancer vaccines, especially when combined with other anticancer
immunotherapies like Ipi, for treatment of a disease that can be so
devastating for so many patients," said Stephen M. Simes, BioSante's
president & chief executive officer.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health and oncology. BioSante's products
include LibiGel(R) (transdermal testosterone gel) for the
treatment of female sexual dysfunction (FSD), specifically hypoactive
sexual desire disorder (HSDD), which is in Phase III clinical
development. BioSante also is developing a portfolio of cancer
vaccines,
with 17 Phase I and Phase II clinical trials currently on-going. Four
of
these vaccines have been granted Orphan Drug designation by the U.S.
Food and Drug Administration (FDA). BioSante's other products include a
testosterone gel for male hypogonadism, for which a New Drug
Application
(NDA) was approved by the FDA on February 14, 2012, which is licensed
to
Teva Pharmaceuticals USA, Inc., and the Pill-Plus(TM), an oral
contraceptive in Phase II clinical development by Pantarhei Bioscience
B.V. BioSante's first FDA-approved product is Elestrin(TM) (estradiol
gel)
indicated for the treatment of hot flashes associated with menopause,
marketed in the U.S. by Jazz Pharmaceuticals, BioSante's licensee.
Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with
information that is not historical, these are forward-looking
statements
under the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, statements about the timing
of a Phase II GVAX Prostate clinical trial and the potential for GVAX
cancer vaccines, and other statements identified by words such as
"anticipates," "will," "continue," "could," "believe," "intends,"
"expects," "plans," "may," "potential," other words of similar meaning,
derivations of such words and the use of future dates. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Uncertainties and risks may cause BioSante's
actual results to be materially different than those expressed in or
implied by BioSante's forward-looking statements. For BioSante,
particular uncertainties and risks include, among others, uncertainties
regarding clinical testing, the difficulty of developing pharmaceutical
products, obtaining regulatory and other approvals and achieving market
acceptance; the marketing and other success of BioSante's licensees or
sublicensees and BioSante's future revenues, if any, from its licensees
and sublicensees; uncertainties relating to the future and costs of
BioSante's product development programs and BioSante's need for and
ability to obtain additional financing if needed. More detailed
information on these and additional factors that could affect
BioSante's
actual results are described in BioSante's filings with the Securities
and Exchange Commission, including its most recent annual report on
Form
10-K and subsequent quarterly reports on Form 10-Q. All
forward-looking statements in this news release speak only as of the
date of this news release and are based on BioSante's current beliefs
and expectations. BioSante undertakes no obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
SOURCE: BioSante Pharmaceuticals, Inc.
For Investors:
The Trout Group LLC
Tricia Swanson, (646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
Copyright Business Wire 2012
**********************************************************************
As of Thursday, 03-01-2012 23:59, the latest Comtex SmarTrend® Alert,
an automated pattern recognition system, indicated a DOWNTREND on
02-22-2012 for BPAX @ $0.72.
For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com
SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright © 2004-2012 Comtex News Network, Inc. All rights reserved.
*** end of story ***
JOEZ still doing well
no worriessssssss have a great weekenddddddddd
LOL i was posting about SLMU
Have u been holding for a year???????????????